Acumen Pharmaceuticals Gestione
Criteri Gestione verificati 4/4
Acumen Pharmaceuticals Il CEO è Dan O'Connell, nominato in Dec2014, e ha un mandato di 11.42 anni. la retribuzione annua totale è $ 1.86M, composta da 34.7% di stipendio e 65.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.41% delle azioni della società, per un valore di $ 699.22K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.5 anni e 6.5 anni.
Informazioni chiave
Dan O'Connell
Amministratore delegato
US$1.9m
Compenso totale
| Percentuale dello stipendio del CEO | 34.68% |
| Mandato del CEO | 11.4yrs |
| Proprietà del CEO | 0.4% |
| Durata media del management | 4.5yrs |
| Durata media del Consiglio di amministrazione | 6.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Oligomer Antibody And Brain Delivery Advances Will Reshape Early Alzheimer Treatment Prospects
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing a beta oligomer targeted antibody therapies for Alzheimer’s disease. What are the underlying business or industry changes driving this perspective?Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Summary Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ABOS for significant market share if successful. Sabirnetug’s Phase 1 trial showed promising results, reducing brain amyloid plaques and supporting its mechanism of action for treating early Alzheimer's disease. Acumen Pharmaceuticals has a healthy cash runway, estimated at 3.5 years, and appears undervalued relative to its peers in the biotech sector. Despite the promising data, investing in ABOS is speculative due to the early stages of research and the potential long timeline to FDA approval. Read the full article on Seeking AlphaIs Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
The shares of microcap biotech Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) more than doubled in value on Wednesday after its rivals Biogen (BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESALY) announced promising late-stage data for experimental Alzheimer's therapy, lecanemab. In the trial involving nearly 1,800 patients, the amyloid targeting monoclonal antibody cut the cognitive and functional decline in the early stage of Alzheimer's by 27%, compared to placebo, the companies announced late Tuesday. With data validating the amyloid hypothesis in Alzheimer's, developers with similar drugs in their pipeline surged in value. Acumen (ABOS) is advancing its only drug candidate, ACU193 for Alzheimer's, with topline data from a Phase 1 trial expected in H1 2023. ACU193 is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers, which, according to the company, are the most toxic and pathogenic form of amyloid-beta.Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
H.C. Wainwright has initiated Acumen Pharmaceuticals (NASDAQ:ABOS) with a buy rating saying the biopharma's early-stage Alzheimer's candidate, ACU193, has promise. The firm has a $15 price target (~207% return based on Wednesday's closing price). Unlike many other Alzheimer's therapies in development -- and marketed ones such as Biogen's (BIIB) Aduhelm (aducanumab) -- that target the removal of beta amyloid plaque from the brain, ACU193 works differently as a anti-amyloid-beta oligomer (AβO) monoclonal antibody. Analyst Andrew Fein noted that ACU193 "lacks the inflammatory effector functions of other [immunoglobulin] subclasses, thereby making it less prone to [amyloid-related imaging abnormalities], a major safety issue with current anti-[amyloid beta] therapies. Acumen (ABOS) said ACU193 prevents toxic AβOs from binding to dendritic spines and preserves neural function. The company added the candidate has the potential for disease slowing as well as cognitive improvement. The ongoing phase 1 trial is expected to enroll 62 subjects with mild cognitive impairment or mild dementia.We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$113m |
| Dec 31 2025 | US$2m | US$646k | -US$121m |
| Sep 30 2025 | n/a | n/a | -US$133m |
| Jun 30 2025 | n/a | n/a | -US$137m |
| Mar 31 2025 | n/a | n/a | -US$116m |
| Dec 31 2024 | US$5m | US$621k | -US$102m |
| Sep 30 2024 | n/a | n/a | -US$82m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$56m |
| Dec 31 2023 | US$4m | US$598k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$49m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$3m | US$570k | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$38m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$1m | US$525k | -US$101m |
| Sep 30 2021 | n/a | n/a | -US$93m |
| Jun 30 2021 | n/a | n/a | -US$92m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$336k | US$240k | -US$7m |
Compensazione vs Mercato: La retribuzione totale di Dan ($USD 1.86M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 1.72M ).
Compensazione vs guadagni: La retribuzione di Dan è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Dan O'Connell (54 yo)
Mr. Daniel J. O’Connell, also known as Dan, MBA was a Key Advisor at Acidophil, LLC. He served as President until February 01, 2024 and serves as Chief Executive Officer of Acumen Pharmaceuticals, Inc. sin...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 11.4yrs | US$1.86m | 0.41% $ 699.2k | |
| President & Chief Development Officer | 2.3yrs | US$1.01m | 0.017% $ 29.5k | |
| CFO & Chief Business Officer | 5yrs | US$948.79k | 0.17% $ 295.9k | |
| Co-Founder | 30.3yrs | US$42.00k | Nessun dato | |
| Co-Founder | no data | Nessun dato | Nessun dato | |
| Co-Founder | no data | Nessun dato | Nessun dato | |
| Chief Operating Officer | 5.3yrs | US$223.68k | 0.087% $ 148.0k | |
| Senior Vice President of Finance & Accounting and Corporate Controller | 2.8yrs | Nessun dato | Nessun dato | |
| VP & Head of Investor Relations | 3.7yrs | Nessun dato | Nessun dato | |
| Chief Legal Officer & Corporate Secretary | 3.7yrs | US$1.48m | 0% $ 0 | |
| Associate Director of Communications | 4yrs | Nessun dato | Nessun dato | |
| Chief People Officer | 5.3yrs | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di ABOS è considerato esperto (durata media dell'incarico 4.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 20.1yrs | US$1.86m | 0.41% $ 699.2k | |
| Member of Clinical & Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Clinical & Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Clinical & Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 7.6yrs | US$107.05k | 0.42% $ 714.2k | |
| Independent Director | 4.1yrs | US$89.11k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 12yrs | US$79.11k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Chairman of the Board | less than a year | US$82.74k | 0% $ 0 | |
| Independent Director | 5.5yrs | US$84.61k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | Nessun dato | Nessun dato |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ABOS sono considerati esperti (durata media dell'incarico 6.5 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 14:43 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Acumen Pharmaceuticals, Inc. è coperta da 7 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jason Zemansky | BofA Global Research |
| Thomas Shrader | BTIG |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |